Helixmith Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Helixmith has been growing earnings at an average annual rate of 13.2%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 3.9% per year.
Wichtige Informationen
13.2%
Wachstumsrate der Gewinne
21.0%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 11.7% |
| Wachstumsrate der Einnahmen | -3.9% |
| Eigenkapitalrendite | -36.8% |
| Netto-Marge | -1,717.4% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Aufschlüsselung der Einnahmen und Ausgaben
Wie Helixmith Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 3,169 | -54,423 | 14,718 | 10,858 |
| 31 Mar 24 | 3,548 | -58,628 | 15,365 | 13,964 |
| 31 Dec 23 | 4,202 | -64,088 | 18,844 | 17,145 |
| 30 Sep 23 | 4,415 | -38,214 | 18,471 | 24,101 |
| 30 Jun 23 | 4,092 | -41,015 | 21,358 | 26,438 |
| 31 Mar 23 | 3,497 | -42,099 | 22,910 | 28,389 |
| 31 Dec 22 | 2,800 | -43,538 | 23,299 | 28,101 |
| 30 Sep 22 | 2,892 | -55,434 | 24,994 | 30,804 |
| 30 Jun 22 | 2,774 | -48,650 | 23,471 | 28,588 |
| 31 Mar 22 | 2,701 | -61,863 | 23,521 | 25,752 |
| 31 Dec 21 | 2,316 | -66,005 | 23,000 | 25,297 |
| 30 Sep 21 | 2,430 | -43,729 | 15,514 | 22,522 |
| 30 Jun 21 | 2,737 | -55,098 | 17,847 | 24,439 |
| 31 Mar 21 | 3,799 | -57,432 | 21,020 | 35,574 |
| 31 Dec 20 | 4,248 | -65,380 | 19,031 | 37,419 |
| 30 Sep 20 | 4,967 | -159,386 | 20,373 | 40,511 |
| 30 Jun 20 | 5,367 | -153,313 | 19,963 | 37,009 |
| 31 Mar 20 | 4,827 | -114,488 | 16,675 | 26,082 |
| 31 Dec 19 | 4,455 | -106,885 | 17,202 | 21,474 |
| 30 Sep 19 | 3,653 | -29,888 | 23,885 | 10,631 |
| 30 Jun 19 | 3,015 | -26,229 | 21,481 | 9,769 |
| 31 Mar 19 | 3,119 | -41,939 | 17,979 | 7,490 |
| 31 Dec 18 | 3,127 | -27,403 | 14,259 | 6,390 |
| 30 Sep 18 | 3,154 | -13,253 | 10,168 | 5,739 |
| 30 Jun 18 | 3,268 | -8,263 | 6,887 | 4,914 |
| 31 Mar 18 | 3,235 | -7,189 | 5,848 | 4,106 |
| 31 Dec 17 | 3,158 | -6,496 | 5,453 | 3,845 |
| 30 Sep 14 | 5,205 | -2,610 | 4,311 | 478 |
| 30 Jun 14 | 5,484 | -842 | 4,199 | 381 |
| 31 Mar 14 | 5,394 | -90 | 4,056 | 452 |
| 31 Dec 13 | 5,746 | 266 | 3,954 | 438 |
Qualität der Erträge: A084990 is currently unprofitable.
Wachsende Gewinnspanne: A084990 is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: A084990 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.2% per year.
Beschleunigtes Wachstum: Unable to compare A084990's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: A084990 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: A084990 has a negative Return on Equity (-36.85%), as it is currently unprofitable.